JP2009535340A - ジメチルフェニル化合物の結晶性形態 - Google Patents

ジメチルフェニル化合物の結晶性形態 Download PDF

Info

Publication number
JP2009535340A
JP2009535340A JP2009507797A JP2009507797A JP2009535340A JP 2009535340 A JP2009535340 A JP 2009535340A JP 2009507797 A JP2009507797 A JP 2009507797A JP 2009507797 A JP2009507797 A JP 2009507797A JP 2009535340 A JP2009535340 A JP 2009535340A
Authority
JP
Japan
Prior art keywords
free base
crystalline free
base form
ethyl
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009507797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535340A5 (enExample
Inventor
ジェニファー ボルトン，
ロバート チャオ，
ミロスラフ ラプタ，
リサ ウィリアムス，
リチャード ディー． ウィルソン，
Original Assignee
セラヴァンス， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス， インコーポレーテッド filed Critical セラヴァンス， インコーポレーテッド
Publication of JP2009535340A publication Critical patent/JP2009535340A/ja
Publication of JP2009535340A5 publication Critical patent/JP2009535340A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2009507797A 2006-04-25 2007-04-24 ジメチルフェニル化合物の結晶性形態 Pending JP2009535340A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79470906P 2006-04-25 2006-04-25
PCT/US2007/010120 WO2007127297A2 (en) 2006-04-25 2007-04-24 Crystalline forms of a dimethylphenyl compound

Publications (2)

Publication Number Publication Date
JP2009535340A true JP2009535340A (ja) 2009-10-01
JP2009535340A5 JP2009535340A5 (enExample) 2011-05-19

Family

ID=38556280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507797A Pending JP2009535340A (ja) 2006-04-25 2007-04-24 ジメチルフェニル化合物の結晶性形態

Country Status (10)

Country Link
US (2) US7880010B2 (enExample)
EP (1) EP2010490B1 (enExample)
JP (1) JP2009535340A (enExample)
CN (1) CN101426765A (enExample)
AR (1) AR060648A1 (enExample)
AT (1) ATE520660T1 (enExample)
CA (1) CA2650631A1 (enExample)
PE (1) PE20080195A1 (enExample)
TW (1) TW200811104A (enExample)
WO (1) WO2007127297A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
MXPA05010379A (es) 2003-03-27 2006-05-31 Bioactis Ltd Aparato para administrar una medicina en polvo en la cavidad intranasal.
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
EP1778626A1 (en) * 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
US20090216010A1 (en) * 2008-02-22 2009-08-27 Wei-Hong Tseng Crystalline carbapenem compound and produced method thereof
CA2758353C (en) * 2009-04-14 2017-06-06 Dean David Edney Process for the preparation of a biphenyl-2-ylcarbamic acid ester
ES2417339T3 (es) 2009-04-23 2013-08-07 Theravance, Inc. Compuestos de diamina que tienen actividad antagonista del receptor muscarinico y agonista del receptor beta2-adrenergico
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
CN105144689B (zh) * 2013-04-26 2018-04-13 富士胶片株式会社 摄像装置及图像显示方法
CN107108502A (zh) * 2015-05-14 2017-08-29 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074246A2 (en) * 2003-02-14 2004-09-02 Theravance Inc. Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2004101525A1 (en) * 2003-05-08 2004-11-25 Theravance, Inc. Crystalline form of aryl aniline beta-2 adrenergic receptor agonist
WO2005051946A2 (en) * 2003-11-21 2005-06-09 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006023454A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. Crystalline form of a biphenyl compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
EP0747355A4 (en) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd NEW CARBAMATES AND MEDICINAL PRODUCTS CONTAINING THEM
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7558576B2 (en) * 2005-03-29 2009-07-07 Qualcomm Incorporated Employing frequency offset to compensate for Doppler shift
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074246A2 (en) * 2003-02-14 2004-09-02 Theravance Inc. Biphenyl derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2004074276A1 (en) * 2003-02-14 2004-09-02 Theravance Inc. BIPHENYL DERIVATIVES HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2004101525A1 (en) * 2003-05-08 2004-11-25 Theravance, Inc. Crystalline form of aryl aniline beta-2 adrenergic receptor agonist
WO2005051946A2 (en) * 2003-11-21 2005-06-09 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2006023454A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. Crystalline form of a biphenyl compound

Also Published As

Publication number Publication date
WO2007127297A3 (en) 2007-12-21
EP2010490B1 (en) 2011-08-17
US20110086881A1 (en) 2011-04-14
ATE520660T1 (de) 2011-09-15
TW200811104A (en) 2008-03-01
WO2007127297A2 (en) 2007-11-08
AR060648A1 (es) 2008-07-02
EP2010490A2 (en) 2009-01-07
CA2650631A1 (en) 2007-11-08
US7880010B2 (en) 2011-02-01
CN101426765A (zh) 2009-05-06
PE20080195A1 (es) 2008-04-04
US20070249674A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
US7880010B2 (en) Crystalline forms of a dimethylphenyl compound
US7687521B2 (en) Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP2421849B1 (en) Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US8173815B2 (en) Biphenyl compounds useful as muscarinic receptor antagonists
US8697724B2 (en) Crystalline oxalate salts of a diamide compound
US20070298112A1 (en) Crystalline forms of a biphenyl compound
BRPI0514413B1 (pt) Sal cristalino de composto de bifenil, sua composição farmacêutica, seus processos de preparação, processo de purificação, usos do referido sal e medicamento.
ES2371425T3 (es) Formas cristalinas de un compuesto de dimetilfenilo.
HK1119672B (en) Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130131